文献速递胸部技术与安全PETCT

18F-FDG PET/CT代谢参数对非小细胞肺癌EGFR突变状态的诊断与预测效能:一项Meta分析

The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: A meta-analysis.
PubMed 文献 · Eur J Radiol · 2021-05-26

本Meta分析纳入18项研究共4024例非小细胞肺癌患者,评估原发灶SUVmax和SUVmean预测EGFR突变状态的效能。SUVmax鉴别EGFR突变型与野生型的汇总敏感度和特异度分别为71%和60%,SUVmean分别为64%和63%;SUVmax和SUVmean的汇总AUROC分别为0.69(95%CI 0.65-0.73)和0.68(95%CI 0.64-0.72)。作者认为原发灶18F-FDG PET/CT的SUVmax和SUVmean对NSCLC的EGFR突变状态具有中等预测效能。

要点

  • 原发灶SUVmax鉴别EGFR突变型与野生型NSCLC的汇总敏感度71%、特异度60%,汇总AUROC为0.69。
  • 原发灶SUVmean的汇总敏感度64%、特异度63%,汇总AUROC为0.68。
  • 对EGFR突变检测结果设盲、阅片者数量和PET/CT扫描仪数量可能是异质性的原因。

核心结论

  • 原发灶18F-FDG PET/CT的SUVmax和SUVmean对NSCLC的EGFR突变状态具有中等预测效能。

研究设计与样本

  • Meta分析,纳入18项研究共4024例患者,检索PubMed/Medline、Embase、Cochrane Library和Web of Science数据库截至2021年1月1日,纳入可构建列联表的研究,采用诊断准确性研究质量评价工具由两名独立评价者进行方法学质量评价。

诊断标准与关键数值

  • SUVmax鉴别EGFR突变型与野生型NSCLC的汇总敏感度71%、特异度60%,汇总AUROC 0.69(95%CI 0.65-0.73)。
  • SUVmean鉴别EGFR突变型与野生型NSCLC的汇总敏感度64%、特异度63%,汇总AUROC 0.68(95%CI 0.64-0.72)。

局限性

  • 对EGFR突变检测结果设盲、阅片者数量和PET/CT扫描仪数量可能是异质性的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the predictive performance of the maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) of primary lesions based on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for EGFR mutation status in patients with non-small cell lung cancer (NSCLC).

METHODS: The PubMed/Medline, Embase, Cochrane Library and Web of Science databases were searched as of January 1, 2021. Studies whose reported data could be used to construct contingency tables were included. Study characteristics were extracted, and methodological quality assessment was conducted by two separate reviewers using the Quality Assessment of Diagnostic Accuracy Studies. The pooled sensitivity, specificity and area under the summary receiver operating characteristic curve (AUROC) were calculated. The possible causes of heterogeneity were analysed by meta-regression.

RESULTS: The 18 included studies had a total of 4024 patients. The majority of the studies showed a low to unclear risk of bias and concerns of applicability. For differentiating EGFR-mutant NSCLC from wild-type NSCLC, the pooled sensitivity and specificity were 71 % and 60 % for SUVmax and 64 % and 63 % for SUVmean, respectively. The summary AUROCs of SUVmax and SUVmean were 0.69 (95 % CI, 0.65-0.73) and 0.68 (95 % CI, 0.64-0.72), respectively. The meta-regression analysis indicated that blindness to EGFR mutation test results, the number of readers and the number of PET/CT scanners were possible causes of heterogeneity.

CONCLUSIONS: Our meta-analysis implied that SUVmax and SUVmean of primary lesions from 18F-FDG PET/CT harboured moderate predictive efficacy for the EGFR mutation status of NSCLC.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Guo Y, Zhu H, Yao Z, et al. The diagnostic and predictive efficacy of 18F-FDG PET/CT metabolic parameters for EGFR mutation status in non-small-cell lung cancer: A meta-analysis. Eur J Radiol. 2021. PMID: 34062472. doi:10.1016/j.ejrad.2021.109792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。